Industry·June 8, 2026

Eli Lilly 340B Deadline Passes, Noncompliant Hospitals Lose Discounts

Eli Lilly's June 1 deadline for hospitals to submit claims data to maintain 340B drug discounts has passed without HRSA intervention. Hospitals that failed to comply with Lilly's data submission requirements will lose access to discounted pricing on covered drugs. HRSA has not responded to requests from hospital and pharmacy groups to intervene in the dispute. The action affects hospitals participating in the 340B program that purchase Lilly medications.

Why it matters for managed care

Medicaid MCOs with contract pharmacy arrangements or safety-net hospital partnerships may see increased drug costs if 340B-eligible hospitals lose discounts and shift utilization or seek higher reimbursement rates.

Pharmacy · Managed Care

Read the full article at beckershospitalreview.com →

Share this briefing